Cargando…

Gene Therapy for Liver Cancers: Current Status from Basic to Clinics

The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamimura, Kenya, Yokoo, Takeshi, Abe, Hiroyuki, Terai, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966544/
https://www.ncbi.nlm.nih.gov/pubmed/31769427
http://dx.doi.org/10.3390/cancers11121865
_version_ 1783488760190599168
author Kamimura, Kenya
Yokoo, Takeshi
Abe, Hiroyuki
Terai, Shuji
author_facet Kamimura, Kenya
Yokoo, Takeshi
Abe, Hiroyuki
Terai, Shuji
author_sort Kamimura, Kenya
collection PubMed
description The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeutic options such as embolization and chemotherapy are not effective against advanced-stage liver cancer; therefore, continuous efforts focus on the development of novel therapeutic options, including molecular targeted agents and gene therapy. In this review, we will summarize the progress toward the development of gene therapies for liver cancer, with an emphasis on recent clinical trials and preclinical studies.
format Online
Article
Text
id pubmed-6966544
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69665442020-01-27 Gene Therapy for Liver Cancers: Current Status from Basic to Clinics Kamimura, Kenya Yokoo, Takeshi Abe, Hiroyuki Terai, Shuji Cancers (Basel) Review The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeutic options such as embolization and chemotherapy are not effective against advanced-stage liver cancer; therefore, continuous efforts focus on the development of novel therapeutic options, including molecular targeted agents and gene therapy. In this review, we will summarize the progress toward the development of gene therapies for liver cancer, with an emphasis on recent clinical trials and preclinical studies. MDPI 2019-11-25 /pmc/articles/PMC6966544/ /pubmed/31769427 http://dx.doi.org/10.3390/cancers11121865 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kamimura, Kenya
Yokoo, Takeshi
Abe, Hiroyuki
Terai, Shuji
Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
title Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
title_full Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
title_fullStr Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
title_full_unstemmed Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
title_short Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
title_sort gene therapy for liver cancers: current status from basic to clinics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966544/
https://www.ncbi.nlm.nih.gov/pubmed/31769427
http://dx.doi.org/10.3390/cancers11121865
work_keys_str_mv AT kamimurakenya genetherapyforlivercancerscurrentstatusfrombasictoclinics
AT yokootakeshi genetherapyforlivercancerscurrentstatusfrombasictoclinics
AT abehiroyuki genetherapyforlivercancerscurrentstatusfrombasictoclinics
AT teraishuji genetherapyforlivercancerscurrentstatusfrombasictoclinics